| Document |
Document Title |
|
WO/2024/086619A2 |
The present disclosure provides for a nucleic acids encoding for a transforming growth factor inhibitor and IL-12. Further provided herein are nucleic acids encoding for chemokine receptor CXCR3. Additionally described herein are oncolyt...
|
|
WO/2024/030962A3 |
Compositions are provided containing at least one mRNA sequence encoding a mutant soluble human Ace2 (hAce2) protein useful in preventing infection with betacoronaviruses, including SARS-CoV2 is provided, as are compositions useful in tr...
|
|
WO/2024/084059A1 |
Methods and products for discovering disease biomarkers and diagnosing disease are provided. RNA or cDNA samples are typically dominated by sequences from highly expressed genes which can negatively affect analysis of the samples. The pr...
|
|
WO/2024/082681A1 |
Provided are a fusion protein, and a nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein. The present invention also relates to a vaccine comprising the fusion protein or the nucleic acid molecule. Furtherm...
|
|
WO/2024/086596A1 |
Provided herein are improved methods, compositions, and systems for editing genomic DNA, including editing genomic DNA by inserting long DNA sequences into genomic DNA.
|
|
WO/2024/059824A3 |
Provided herein are recombinant nucleic acids that reduce expression of CD5, CBLB, CISH, DGKA, DGKZ, DNMT3A, MAP4K1, NR4A1, PTPN2, TET2, or ZC3H12A and cells comprising such recombinant nucleic acids. Also provided are methods of making ...
|
|
WO/2024/036105A3 |
A method of generating cells of the T cell lineage is provided that involves culturing a sample comprising stem cells or progenitor cells with an engineered Notch ligand conjugated to a suspension support and isolating cells of the T cel...
|
|
WO/2024/083870A1 |
There is provided an Aβ peptide binding polypeptide, which comprises an amino acid sequence selected from i) and ii), wherein: i) is SEQ ID NO:1 – [LINK] – SEQ ID NO:2; ii) is SEQ ID NO:3 – [LINK] – SEQ ID NO:4; and [LINK] is a ...
|
|
WO/2024/086713A1 |
The present disclosure relates to compositions, such as siRNA molecules and FN3 domains conjugated to the same, as well as methods of making and using the molecules.
|
|
WO/2024/082060A1 |
The present disclosure provides trivalent and trispecific antibody constructs capable of binding two different antigens on one or more cytotoxic effector cell(s) and a tumor-associated antigen (TAA) on a tumor cell. Pharmaceutical compos...
|
|
WO/2024/086848A2 |
The present invention generally relates to compositions comprising a CRISPR based regulatory element comprising a barcode sequence that serves as a binding site for a Cas9/gRNA molecule and which alters expression of a downstream gene wh...
|
|
WO/2023/230598A3 |
Disclosed are methods of producing recombinant feline morbillivirus (FeMV) using reverse genetics. In some aspects, the methods comprise: (a) extracting FeMV RNA from an isolated FeMV positive sample, (b) generating cDNAs from the FeMV R...
|
|
WO/2024/085143A1 |
The purpose of the present invention is to provide a novel peptide that could be used to induce an immune response to SARS-CoV-2. A nucleocapsid-derived antigen peptide according to the present disclosure includes the following polypep...
|
|
WO/2024/031058A3 |
Disclosed is a method of treating a subject who has a neurological disease. The neurological disease may be associated with altered FOXG1 expression. In one aspect, the method includes a step of administering an effective dose of a FOXG1...
|
|
WO/2024/059707A3 |
The present disclosure includes certain steps in immunoassays, such as immunoassays based on chemiluminescence, which increase assay sensitivity as based on a variety of metrics including increasing signal to noise and decreasing limits ...
|
|
WO/2024/044672A3 |
The present disclosure provides a versatile and multi-functional platform for transcriptome regulation using the RNA-guided, RNA-targeting activity of type VI-D CRISPR effectors with RNA-guided RNA endonuclease activity combined with gui...
|
|
WO/2024/085079A1 |
[Problem] SMN2 gene located in the vicinity of SMN1 gene is different from the SMN1 gene by only 5 bases. Thus, in order to perform an SMA screening test, it was necessary to establish a test system that can detect the SMN1 gene specific...
|
|
WO/2024/015877A9 |
Disclosed herein are recombinant AAV variant (e.g., variant serotype 3B (AAV3B)) capsid proteins and variant capsid protein-containing viral particles with enhanced ability to transduce hepatic cells. Viral particles containing these cap...
|
|
WO/2024/084785A1 |
The purpose of the present invention is to provide a composition having higher efficacy and safety and suitable for use as a RS virus vaccine. Provided is a composition containing G protein and a CpG oligodeoxynucleotide of a RS virus,...
|
|
WO/2024/084516A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop structure...
|
|
WO/2024/086352A2 |
Among other things, the present disclosure provides compositions, e.g., isolated nucleic acids, vectors, and recombinant adeno-associated viruses (rAAVs), comprising a nucleic acid sequence encoding a PRPF31 polypeptide. In some embodime...
|
|
WO/2024/086530A1 |
Described herein are chocolate compositions comprising sweet proteins, such as sweet polypeptides (e.g., brazzein, brazzein-53, brazzein-54, or a combination of brazzein-53 and brazzein-54), and method of producing the same.
|
|
WO/2023/230557A3 |
Gene therapy compositions and methods related to transposition are provided, e.g., those engineered from Eptesicus fuscus.
|
|
WO/2024/084441A1 |
The present disclosure provides methods, compositions, and kits for the treatment or prevention of an HIV infection in a human having or at risk of having HIV, comprising the combination of the HTI immunogen and at least one stable solub...
|
|
WO/2024/085674A1 |
The present invention relates to a fusion protein containing a CAS protein and a bacterial toxin, and a use thereof. A fusion protein, a polypeptide thereof, and a CRISPR-Cas system including same according to the present invention allow...
|
|
WO/2024/040072A3 |
Various peroxidases are useful in treating subjects suffering from diseases associated with buildup of bisretinoids. The disclosed peroxidases may also be useful in activating prodrugs. The disclosed peroxidases may be administered as ma...
|
|
WO/2024/085671A1 |
The present application relates to a mutant ribonuclease activity regulating protein and a method for producing L-valine using same.
|
|
WO/2024/084394A1 |
Compounds and methods are provided for facilitating delivery of an oligonucleotide, for example, into a nucleus and/or cytosol of a cell.
|
|
WO/2024/084520A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one first hairpin loop str...
|
|
WO/2024/086650A1 |
SnRNA systems comprising RNA binding sequences for RNA editing are disclosed herein.
|
|
WO/2024/057094A3 |
Human interleukin-2 (IL-2) muteins or variants thereof are provided. Also provided are pharmaceutical compositions that include such IL-2 muteins.
|
|
WO/2024/030456A3 |
The disclosure provides nucleic acid constructs for cell- and tissue-specific targeting of therapeutic and diagnostic agents.
|
|
WO/2024/085533A1 |
The present invention pertains to: a composition for improving the efficiency of introducing vectors into cells by using lunasin; and a method for introducing vectors into cells with high efficiency by using said composition.
|
|
WO/2024/086342A1 |
The present disclosure provides methods for generating and/or purifying secretomes, extracellular vesicles, and fractions thereof, from progenitor cells; and provides compositions containing such generated secretomes, extracellular vesic...
|
|
WO/2024/006824A3 |
Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the pre...
|
|
WO/2024/044708A3 |
Methods and compositions for reducing expansion of nucleotide repeats in a cell, comprising base editors and a guide RNA (gRNA) that directs the Cas-based enzyme to the splice acceptor site for mutL homolog 3 (MLH3) exon 7 or to the MLH3...
|
|
WO/2024/082003A1 |
The present invention relates generally to compositions and methods for inhibiting the replication of coronaviruses and treating diseases caused by coronavirus infection. More specifically, the invention provides nucleic acids capable of...
|
|
WO/2024/085182A1 |
The present invention addresses the problem of providing a novel method for treating T cell tumor, whereby it becomes possible to induce the cell damage of a tumor cell and which is less likely to cause immunodeficiency. According to t...
|
|
WO/2024/086586A2 |
The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject.
|
|
WO/2024/044691A3 |
Disclosed herein are compositions comprising chemically modified adeno-associated viruses (AAV) engineered by chemical modification of capsid proteins, whether wildtype or engineered, and methods of using such modified AAVs for therapeut...
|
|
WO/2024/020320A3 |
The present disclosure relates to circular, non-viral DNA vectors, compositions including one or more of the disclosed vectors, and methods for delivering and/or expressing one or more therapeutic genes (e.g., proteins) in mammals, e.g.,...
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/083226A1 |
An activatable antibody fusion protein, said fusion protein comprising an antibody portion specifically binding to a target, an immunoglobulin Fc portion, a masking portion and a cytokine portion. The present invention further relates to...
|
|
WO/2024/086633A1 |
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of DM1 protein kinase (DMPK) gene. The DMPK RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a DMPK gene. Pharma...
|
|
WO/2024/083579A1 |
The current disclosure generally relates to the technical field of plant molecular biology and provides methods for the production of high expressing promoters and the production of plants with enhanced expression of nucleic acids wherei...
|
|
WO/2024/044725A3 |
The present invention relates to recombinant adeno-associated viruses (rAAVs) having capsid proteins engineered to include amino acid sequences that confer and/or enhance desired properties. In particular, the invention provides engineer...
|
|
WO/2024/059630A3 |
The present disclosure relates to a method for treating cancer in a subject that is BRCA-negative and homologous repair proficient (HRP), the method comprising administering to the subject a nucleic acid vector (e.g., a plasmid) comprisi...
|
|
WO/2024/036204A3 |
Disclosed herein are antibodies having variations for increased expression and recombinant nucleic acid sequences that encode the antibodies. The disclosure also provides methods of preventing and/or treating a disease or disorder in a s...
|
|
WO/2024/082269A1 |
Provided are an application of a bispecific antibody in immune cell therapy, and a method for improving immune cell killing activity.
|
|
WO/2024/084932A1 |
[Problem] To provide a new carrier peptide fragment having cell membrane permeability. [Solution] The carrier peptide fragment disclosed herein is introduced into at least the cytoplasm of a eukaryotic cell from outside the cell and comp...
|
